<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960970</url>
  </required_header>
  <id_info>
    <org_study_id>Prophylaxis Trial</org_study_id>
    <nct_id>NCT03960970</nct_id>
  </id_info>
  <brief_title>Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries</brief_title>
  <official_title>Azithromycin-based Extended-spectrum Prophylaxis in Scheduled Cesarean Deliveries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWJ Barnabas Health at Jersey City Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWJ Barnabas Health at Jersey City Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cesarean deliveries are the most common surgical procedure performed in the United States. A
      significant decrease in cesarean delivery associated maternal morbidity has been achieved
      with preoperative prophylactic single-dose cephalosporin, widely used before skin incision.
      Also, on laboring patients and/or with rupture of membranes, several studies suggest that
      adding azithromycin to standard cephalosporin prophylaxis is cost-effective and reduces
      overall rates of endometritis, wound infection, readmission, use of antibiotics and serious
      maternal events. Azithromycin has effective coverage against Ureaplasma, associated with
      increased rates of endometritis. Although two-drug regimen has been suggested for laboring
      and/or patients that undergo cesarean delivery, no studies have investigated the potential
      benefits of two-drug regimen in non-laboring patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cesarean deliveries are the most common surgical procedure performed in the United States,
      and scheduled cesarean deliveries account for at least 40% of all cesarean deliveries every
      year. A significant decrease in cesarean delivery associated maternal morbidity has been
      achieved with preoperative prophylactic single-dose cephalosporin given within 60 minutes of
      skin incision. Also, on laboring patients and/or with rupture of membranes, several studies
      suggest that adding azithromycin to standard cephalosporin prophylaxis is not only
      cost-effective but reduces overall rates of endometritis and wound infection. Azithromycin
      provides effective coverage against Ureaplasma, commonly associated with increased rates of
      endometritis. Although two-drug regimen has been suggested for laboring and/or patients that
      undergo cesarean delivery, no studies have investigated the potential benefits of two-drug
      regimen in non-laboring patients. No increase in neonatal morbidity was noted with adjunctive
      azithromycin prophylaxis, including adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pregnant patients admitted to Labor and Delivery unit between June 2019 and July 2020 will be randomized to received either standard prophylaxis or azithromycin and cephalosporin for preoperative prophylaxis after inclusion and exclusion criteria are met and informed consent for participation is signed.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Endometritis</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of Wound Infection</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis. Wound hematoma, seroma, abscess or breakdown alone in the absence of the preceding signs did not constitute infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Maternal Fever</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Temperature equal or greater than 100.4F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Maternal Postpartum Readmission or Unscheduled Visit</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Admission to hospital or unscheduled appointment in additional to regular 1-week and 6-week postpartum visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Postpartum Antibiotic Use</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Antibiotic use for any reason including other infections such as UTI and sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Serious Adverse Events</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>MICU admission, thromboembolic events, sepsis, maternal death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rates of Neonatal Intensive Care Unit (NICU) Admission</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Neonatal Intensive Care Unit (NICU) Admission rather than prematurity</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of Neonatal Readmission</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Hospital readmission within 6 weeks of birth</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Endometritis</condition>
  <condition>Cesarean Section; Infection</condition>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>One-drug Prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mefoxin 2g IV, Piggyback, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two-drug Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 500 mg</intervention_name>
    <description>Additional IV Azithromycin 500 mg to Standard Prophylaxis</description>
    <arm_group_label>Two-drug Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefoxin 2g</intervention_name>
    <description>Standard Prophylaxis</description>
    <arm_group_label>One-drug Prophylaxis</arm_group_label>
    <arm_group_label>Two-drug Prophylaxis</arm_group_label>
    <other_name>Cefoxitin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women 18 years or older

          -  Women undergoing primary or repeat cesarean delivery

          -  Singleton gestation

          -  Gestational age greater than 34 weeks

          -  Pregnant patients undergoing scheduled cesarean delivery

          -  Intact membranes

          -  Non-laboring

          -  Signed informed consent

        Exclusion Criteria:

          -  Maternal age &lt; 18 years

          -  Multi-fetal gestation

          -  Known allergy to cephalosporin or azithromycin

          -  Patient unwilling or unable to provide consent

          -  Diagnosis of rupture of membranes

          -  Intraamniotic infection, or any other active bacterial infection (e.g. pyelonephritis,
             pneumonia, abscess) at time of randomization.

          -  Immunocompromising medical conditions: HIV positive with CD4 count below 200, chronic
             steroid use, current diagnosis of cancer and/or chemotherapy age use

          -  Emergent cesarean precluding consent or availability of study medication

          -  Need for hysterectomy at time of delivery

          -  Use of antibiotic in the 72 hours prior to admission, with exception to patient
             receiving antibiotics for GBS

          -  Inability to contact patient on postpartum period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tali Wajsfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWJ Barnabas Health at Jersey City Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tali Wajsfeld, MD</last_name>
    <phone>2019152000</phone>
    <phone_ext>2340</phone_ext>
    <email>tali.wajsfeld@rwjbh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jersey City Medical Center</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tali Wajsfeld, MD</last_name>
      <phone>201-915-2340</phone>
      <email>tali.wajsfeld@rwjbh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009 Mar;113(3):675-82. doi: 10.1097/AOG.0b013e318197c3b6. Review.</citation>
    <PMID>19300334</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol. 2003 Jun;101(6):1183-9.</citation>
    <PMID>12798523</PMID>
  </reference>
  <reference>
    <citation>Boggess KA, Tita A, Jauk V, Saade G, Longo S, Clark EA, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Blackwell S, Beamon C, Szychowski JM, Andrews W; Cesarean Section Optimal Antibiotic Prophylaxis Trial Consortium. Risk Factors for Postcesarean Maternal Infection in a Trial of Extended-Spectrum Antibiotic Prophylaxis. Obstet Gynecol. 2017 Mar;129(3):481-485. doi: 10.1097/AOG.0000000000001899.</citation>
    <PMID>28178058</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044.</citation>
    <PMID>27682034</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Shah SR, Goldenberg RL, Cliver SP, Hauth JC, Cassell GH. Association of post-cesarean delivery endometritis with colonization of the chorioamnion by Ureaplasma urealyticum. Obstet Gynecol. 1995 Apr;85(4):509-14.</citation>
    <PMID>7898825</PMID>
  </reference>
  <reference>
    <citation>Harper LM, Kilgore M, Szychowski JM, Andrews WW, Tita ATN. Economic Evaluation of Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. Obstet Gynecol. 2017 Aug;130(2):328-334. doi: 10.1097/AOG.0000000000002129.</citation>
    <PMID>28697108</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008 Jan;111(1):51-6. doi: 10.1097/01.AOG.0000295868.43851.39.</citation>
    <PMID>18165392</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011 Jun;117(6):1472-83. doi: 10.1097/AOG.0b013e3182238c31.</citation>
    <PMID>21606770</PMID>
  </reference>
  <reference>
    <citation>Skeith AE, Niu B, Valent AM, Tuuli MG, Caughey AB. Adding Azithromycin to Cephalosporin for Cesarean Delivery Infection Prophylaxis: A Cost-Effectiveness Analysis. Obstet Gynecol. 2017 Dec;130(6):1279-1284. doi: 10.1097/AOG.0000000000002333.</citation>
    <PMID>29112658</PMID>
  </reference>
  <reference>
    <citation>Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open. 2015 Dec 9;5(12):e008194. doi: 10.1136/bmjopen-2015-008194. Review.</citation>
    <PMID>26656010</PMID>
  </reference>
  <reference>
    <citation>Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. Am J Obstet Gynecol. 2015 Jun;212(6):812.e1-6. doi: 10.1016/j.ajog.2015.01.015. Epub 2015 Jan 13.</citation>
    <PMID>25595580</PMID>
  </reference>
  <reference>
    <citation>Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014 Oct 28;(10):CD007482. doi: 10.1002/14651858.CD007482.pub3. Review.</citation>
    <PMID>25350672</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RWJ Barnabas Health at Jersey City Medical Center</investigator_affiliation>
    <investigator_full_name>Tali Wajsfeld</investigator_full_name>
    <investigator_title>Principal Investigador</investigator_title>
  </responsible_party>
  <keyword>Cesarean Delivery</keyword>
  <keyword>Endometritis</keyword>
  <keyword>Wound Infection</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Antibiotic Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

